Literature DB >> 10529723

Kinetic and equilibrium analyses of [(123)I]epidepride binding to striatal and extrastriatal dopamine D(2) receptors.

M Fujita1, J P Seibyl, N P Verhoeff, M Ichise, R M Baldwin, S S Zoghbi, C Burger, J K Staley, N Rajeevan, D S Charney, R B Innis.   

Abstract

Quantitative SPECT measures of dopamine D(2) like receptors with [(123)I]epidepride is complicated by its high affinity and lipophilic metabolites. The purpose of this study was to use both parent (P) and lipophilic metabolites (M) as input functions in a kinetic paradigm and in comparison to the results of equilibrium studies. Kinetic studies on eleven healthy human subjects, ages 32+/- 10 were performed following i.v. injection of approximately 370 MBq of [(123)I]epidepride. Images were acquired for 13.5+/-1.0 hours. Equilibrium studies were done on seven of eleven subjects with a bolus injection of approximately 140 MBq, bolus/infusion ratio of 10 hours, and infusion for 30-32 hours. High (striatum) and low (temporal cortex) density regions were studied. Two (P and M) and one (P) input function models were applied in the kinetic studies. In receptor-rich regions, the distribution volumes in nondisplaceable compartments were fixed to those in cerebellum. In addition, in the two input function model, K(1)(P)/K(1)(M) was fixed to the values in the cerebellum. The one input function model provided V'(3) values (=f(1)*B'(max)/K(D)) which were consistent with those obtained in equilibrium studies in both receptor-rich regions, while the two input function model provided consistent values only in striatum. Poor identifiability of the rate constants of metabolites seemed to be the source of errors in the two input function model. These results suggest that correct V'(3) values can be obtained with the one input function model both in high- and low-density regions. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10529723     DOI: 10.1002/(SICI)1098-2396(19991215)34:4<290::AID-SYN5>3.0.CO;2-B

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  19 in total

1.  Effect of scatter correction on the compartmental measurement of striatal and extrastriatal dopamine D2 receptors using [123I]epidepride SPET.

Authors:  Masahiro Fujita; Andrea Varrone; Kyeong Min Kim; Hiroshi Watabe; Sami S Zoghbi; Nicholas Seneca; Dnyanesh Tipre; John P Seibyl; Robert B Innis; Hidehiro Iida
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-01-17       Impact factor: 9.236

2.  Kinetic modeling of [18 F]VAT, a novel radioligand for positron emission tomography imaging vesicular acetylcholine transporter in non-human primate brain.

Authors:  Hongjun Jin; Xuyi Yue; Hui Liu; Junbin Han; Hubert Flores; Yi Su; Stanley M Parsons; Joel S Perlmutter; Zhude Tu
Journal:  J Neurochem       Date:  2018-03-25       Impact factor: 5.372

3.  Kinetic analysis in human brain of [11C](R)-rolipram, a positron emission tomographic radioligand to image phosphodiesterase 4: a retest study and use of an image-derived input function.

Authors:  Paolo Zanotti-Fregonara; Sami S Zoghbi; Jeih-San Liow; Elise Luong; Ronald Boellaard; Robert L Gladding; Victor W Pike; Robert B Innis; Masahiro Fujita
Journal:  Neuroimage       Date:  2010-10-26       Impact factor: 6.556

4.  Brain and whole-body imaging of nociceptin/orphanin FQ peptide receptor in humans using the PET ligand 11C-NOP-1A.

Authors:  Talakad G Lohith; Sami S Zoghbi; Cheryl L Morse; Maria F Araneta; Vanessa N Barth; Nancy A Goebl; Johannes T Tauscher; Victor W Pike; Robert B Innis; Masahiro Fujita
Journal:  J Nucl Med       Date:  2012-02-06       Impact factor: 10.057

5.  [(11)C]TASP457, a novel PET ligand for histamine H3 receptors in human brain.

Authors:  Yasuyuki Kimura; Chie Seki; Yoko Ikoma; Masanori Ichise; Kazunori Kawamura; Keisuke Takahata; Sho Moriguchi; Tomohisa Nagashima; Tatsuya Ishii; Soichiro Kitamura; Fumitoshi Niwa; Hironobu Endo; Makiko Yamada; Makoto Higuchi; Ming-Rong Zhang; Tetsuya Suhara
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-02-23       Impact factor: 9.236

6.  Brain and whole-body imaging in rhesus monkeys of 11C-NOP-1A, a promising PET radioligand for nociceptin/orphanin FQ peptide receptors.

Authors:  Yasuyuki Kimura; Masahiro Fujita; Jinsoo Hong; Talakad G Lohith; Robert L Gladding; Sami S Zoghbi; Johannes A Tauscher; Nancy Goebl; Karen S Rash; Zhaogen Chen; Concepcion Pedregal; Vanessa N Barth; Victor W Pike; Robert B Innis
Journal:  J Nucl Med       Date:  2011-08-30       Impact factor: 10.057

7.  11C-ER176, a Radioligand for 18-kDa Translocator Protein, Has Adequate Sensitivity to Robustly Image All Three Affinity Genotypes in Human Brain.

Authors:  Masamichi Ikawa; Talakad G Lohith; Stal Shrestha; Sanjay Telu; Sami S Zoghbi; Sabrina Castellano; Sabrina Taliani; Federico Da Settimo; Masahiro Fujita; Victor W Pike; Robert B Innis
Journal:  J Nucl Med       Date:  2016-11-17       Impact factor: 10.057

8.  Imaging for metabotropic glutamate receptor subtype 1 in rat and monkey brains using PET with [18F]FITM.

Authors:  Tomoteru Yamasaki; Masayuki Fujinaga; Jun Maeda; Kazunori Kawamura; Joji Yui; Akiko Hatori; Yuichiro Yoshida; Yuji Nagai; Masaki Tokunaga; Makoto Higuchi; Tetsuya Suhara; Toshimitsu Fukumura; Ming-Rong Zhang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-11-24       Impact factor: 9.236

9.  In vivo affinity of [18F]fallypride for striatal and extrastriatal dopamine D2 receptors in nonhuman primates.

Authors:  Mark Slifstein; Dah-Ren Hwang; Yiyun Huang; Ningning Guo; Yasuhiko Sudo; Raj Narendran; Peter Talbot; Marc Laruelle
Journal:  Psychopharmacology (Berl)       Date:  2004-09       Impact factor: 4.530

10.  Dopamine D2 receptor levels in striatum, thalamus, substantia nigra, limbic regions, and cortex in schizophrenic subjects.

Authors:  Robert M Kessler; Neil D Woodward; Patrizia Riccardi; Rui Li; M Sib Ansari; Sharlett Anderson; Benoit Dawant; David Zald; Herbert Y Meltzer
Journal:  Biol Psychiatry       Date:  2009-02-28       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.